In the alchemy of pharmaceutical success, the most potent compound must be examined not merely for its therapeutic index but for the full constellation of manufacturing, competitive, and regulatory forces
A systematic examination of Eli Lilly’s risk landscape reveals ten material risk categories that define the company’s vulnerability profile. These risks span clinical, regulatory, operational, commercial, financial, and
